1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Cash & equivalents declining -26.68% while Biotechnology shows -5.49% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -8.49%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-27.05%
Current assets growth ≥ 1.5x the Biotechnology median of -7.23%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-7.44%
PP&E growth ≥ 1.5x the Biotechnology median of -1.40%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-5.69%
≥ 1.5x the Biotechnology median of -0.50%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
≥ 1.5x the Biotechnology median of -4.95%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
9.15%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-74.86%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Above 1.5x Biotechnology median of 3.06%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Above 1.5x Biotechnology median of -0.23%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Above 1.5x Biotechnology median of 1.43%. Jim Chanos suspects an alarming rise in overall leverage.
1.65%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.34%
0.5-0.75x Biotechnology median of -5.27%. Guy Spier is cautious about weaker retention vs. peers.
-6.51%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
≥ 1.5x Biotechnology median of -7.70%. Joel Greenblatt sees stronger equity growth vs. peers.
-25.21%
≥ 1.5x Biotechnology median of -5.02%. Joel Greenblatt sees more aggressive expansions than peers.
-100.00%
Below half Biotechnology median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-11.75%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
27.85%
Above 1.5x Biotechnology median 8.01%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
